Martina Pennisi
Overview
Explore the profile of Martina Pennisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Oct;
29(11):2954.
PMID: 36253610
No abstract available.
12.
Riedell P, Hwang W, Nastoupil L, Pennisi M, McGuirk J, Maziarz R, et al.
Transplant Cell Ther
. 2022 Jul;
28(10):669-676.
PMID: 35850429
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-directed chimeric antigen receptor (CAR) T cell therapies approved for the treatment of relapsed/refractory aggressive B cell lymphomas. We present a multicenter retrospective...
13.
Monfrini C, Stella F, Aragona V, Magni M, Ljevar S, Vella C, et al.
Clin Cancer Res
. 2022 May;
28(15):3378-3386.
PMID: 35583610
Purpose: In clinical trials, the expansion and persistence of chimeric antigen receptor (CAR) T cells correlate with therapeutic efficacy. However, properties of CAR T cells that enable their in vivo...
14.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Mar;
28(4):713-723.
PMID: 35288695
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and...
15.
Pennisi M, Sanchez-Escamilla M, Flynn J, Shouval R, Tomas A, Silverberg M, et al.
Blood Adv
. 2021 Aug;
5(17):3397-3406.
PMID: 34432870
Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation...
16.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al.
Haematologica
. 2021 Jul;
107(5):1153-1162.
PMID: 34289655
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (double expressor lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of...
17.
Tomas A, Whiting K, Maloy M, Ruiz J, Devlin S, Sanchez-Escamilla M, et al.
Bone Marrow Transplant
. 2021 Jul;
56(11):2749-2754.
PMID: 34253878
The post-transplant scoring system (PTSS), developed by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, is based on three independent post-transplant risk factors: grade of acute graft-versus-host disease,...
18.
Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, et al.
Transplant Cell Ther
. 2021 Mar;
27(3):233-240.
PMID: 33781518
CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T cell therapy is associated with early...
19.
Sermer D, Batlevi C, Palomba M, Shah G, Lin R, Perales M, et al.
Blood Adv
. 2020 Oct;
4(19):4669-4678.
PMID: 33002134
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2...
20.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T, et al.
Blood Adv
. 2020 Aug;
4(15):3776-3787.
PMID: 32780846
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell...